The gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9)—which binds and targets LDLR for lysosomal degradation—also underlie a subclass of familial hypercholesterolemia. This evidence concerns the gene LDLR and familial hypercholesterolemia.